Effect of exogenous ubiquinone-10 on the ubiquinone pool of liver and spleen of mice

Bliznakov, Emile G.; Casey, Adria C.

doi:10.1016/0304-4165(74)90225-6

Cited by 2 publications

(4 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CoQ 10 is found in most tissues at varying concentrations [33,34] that decrease with age and in some pathological condi- tions owing to increased requirements, decreased production [35] or insufficient intake of the chemical precursors needed for its synthesis [36,38,39]. The rationale for combining CoQ 10 and IFN lies in the scope for sustaining and enhancing the intensity of the immune response over time by providing an additional energy supply [20][21][22][23]27,[55][56][57][58].…”

Section: Discussionmentioning

confidence: 98%

“…To be effective, the immune response initiated by IFN seems to require large amounts of ATP, which is essential for the production of antibodies [26][27][28][29][30][31][32][33][34][35][36][37][38][39]. It has been hypothesized that the failure of some patients to respond 0960-8931 c 2007 Lippincott Williams & Wilkins to IFN therapy may be related to an inability to meet the demand for extra ATP induced by this agent [24][25][26].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Recombinant interferon α-2b and coenzyme Q10 as a postsurgical adjuvant therapy for melanoma: a 3-year trial with recombinant interferon-α and 5-year follow-up

et al. 2007

View full text Add to dashboard Cite

Early surgical intervention remains the most successful therapy for melanoma. Despite better outcomes observed in soft tissue and lymph node metastases, the results of pharmacological therapies are still disappointing. Currently, there is no standard adjuvant therapy for melanoma. Low concentrations of coenzyme Q10 have been demonstrated in melanoma cell lines and in sera of melanoma patients. These data and the results of clinical trials of patients with other advanced cancers prompted this study of the long-term administration of an optimized dose of recombinant interferon alpha-2b and coenzyme Q10 to patients with stage I and II melanoma. A 3-year trial envisaging uninterrupted treatment with low-dose recombinant interferon alpha-2b (9 000 000 000 IU weekly) administered twice daily and coenzyme Q10 (400 mg/day) was conducted in patients with stage I and II melanoma (American Joint Committee on Cancer criteria 2002) and surgically removed lesions. Treatment efficacy was evaluated as incidence of recurrences at 5 years. All patients completed the treatment and the follow-up. Significantly different rates of disease progression were observed in the interferon+coenzyme Q10 and the interferon group for both stages. No patient withdrew from the study owing to side effects. Long-term administration of an optimized dose of recombinant interferon alpha-2b in combination with coenzyme Q10 seemed to induce significantly decreased rates of recurrence and had negligible adverse effects. A survival study could not be undertaken owing to the small patient sample and the short duration of follow-up.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

Recombinant interferon α-2b and coenzyme Q10 as a postsurgical adjuvant therapy for melanoma: a 3-year trial with recombinant interferon-α and 5-year follow-up

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Moreover, it was found that the state of the immune system depends on the level of ubiquinones in the animal tissues [12]. There is reason to believe that ubiquinones are activators of the immune processes.…”

Section: Introductionmentioning

confidence: 99%

“…The concentration of ubiquinones is one of the factors regulating the protein content in the tissues of animals in their life-span [11]. Moreover, it was found that the state of the immune system depends on the level of ubiquinones in the animal tissues [12]. There is reason to believe that ubiquinones are activators of the immune processes.…”

Section: Introductionmentioning

confidence: 99%

The role of ubiquinones in the regulation of lipid metabolism in rat thymocytes

Новоселова¹

1989

FEBS Letters

View full text Add to dashboard Cite

The effect of ubiquinones Q-l, Q-2, Q-8 and Q-9 on lipid metabolism in rat thymocytes in vitro was studied. The cells were incubated in a medium containing ubiquinones within the concentration range from 1 to 100 #M. A 2-fold decreased cholesterol synthesis was observed in thymocytes incubated with ubiquinone Q-9 at a concentration of exogenous ubiquinone of no less than 40 #M. Incubation of thymocytes with ubiquinones UQ-I and UQ-2 that are characteristic of rats (40 #M and I00/tM) resulted in a decrease of cholesterol synthesis. Ubiquinone-8 had a tendency to inhibit the cholesterogenesis in rat thymocytes.

show abstract

Effect of exogenous ubiquinone-10 on the ubiquinone pool of liver and spleen of mice

Cited by 2 publications

References 3 publications

Recombinant interferon α-2b and coenzyme Q10 as a postsurgical adjuvant therapy for melanoma: a 3-year trial with recombinant interferon-α and 5-year follow-up

Recombinant interferon α-2b and coenzyme Q10 as a postsurgical adjuvant therapy for melanoma: a 3-year trial with recombinant interferon-α and 5-year follow-up

The role of ubiquinones in the regulation of lipid metabolism in rat thymocytes

Contact Info

Product

Resources

About